Sanofi Buys Provention Bio and its Type 1 Diabetes Drug for US$2.9 B
By Lucy Haggerty
Pharma Deals Review: Vol 2023 Issue 3 (Table of Contents)
Published: 24 Mar-2023
DOI: 10.3833/pdr.v2023.i3.2772 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a return to diabetes R&D, Sanofi has agreed to acquire Provention Bio for US$25 per share in cash, representing a total equity value of approximately US$2...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS